Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0588 | 0.4584 | 1 |
Giardia lamblia | AAA family ATPase | 0.06 | 0.4742 | 0.5 |
Mycobacterium ulcerans | ATPase | 0.06 | 0.4742 | 0.5 |
Trypanosoma cruzi | Valosin-containing protein, putative | 0.0951 | 0.9326 | 0.5 |
Schistosoma mansoni | cell division control protein 48 aaa family protein | 0.0951 | 0.9326 | 0.9122 |
Leishmania major | Transitional endoplasmic reticulum ATPase, putative,valosin-containing protein homolog | 0.0951 | 0.9326 | 0.5 |
Plasmodium falciparum | cell division cycle protein 48 homologue, putative | 0.0951 | 0.9326 | 0.5 |
Schistosoma mansoni | cell division control protein 48 aaa family protein | 0.1003 | 1 | 1 |
Brugia malayi | vesicle-fusing ATPase | 0.0588 | 0.4584 | 1 |
Echinococcus multilocularis | transitional endoplasmic reticulum atpase | 0.1003 | 1 | 1 |
Entamoeba histolytica | transitional endoplasmic reticulum ATPase, putative | 0.0951 | 0.9326 | 0.5 |
Brugia malayi | valosin containing protein | 0.0588 | 0.4584 | 1 |
Trichomonas vaginalis | spermatogenesis associated factor, putative | 0.1003 | 1 | 1 |
Onchocerca volvulus | Transitional endoplasmic reticulum ATPase homolog | 0.1003 | 1 | 0.5 |
Trypanosoma brucei | Valosin-containing protein | 0.0951 | 0.9326 | 0.5 |
Loa Loa (eye worm) | vesicle-fusing ATPase | 0.0588 | 0.4584 | 1 |
Mycobacterium tuberculosis | Putative conserved ATPase | 0.06 | 0.4742 | 0.5 |
Plasmodium vivax | cell division cycle protein 48 homologue, putative | 0.0951 | 0.9326 | 1 |
Entamoeba histolytica | cdc48-like protein, putative | 0.0951 | 0.9326 | 0.5 |
Toxoplasma gondii | cell division protein CDC48CY | 0.1003 | 1 | 1 |
Toxoplasma gondii | cell division protein CDC48AP | 0.06 | 0.4742 | 0.0000097958 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.